Please login to the form below

Not currently logged in
Email:
Password:

clinical care

This page shows the latest clinical care news and features for those working in and with pharma, biotech and healthcare.

Pfizer, Flynn face reinstatement of £90m CMA fine

Pfizer, Flynn face reinstatement of £90m CMA fine

knock-on effect on the resources of clinical commissioning groups and patient care".

Latest news

More from news
Approximately 0 fully matching, plus 117 partially matching documents found.

Latest Intelligence

  • Novel endpoints in the digital age Novel endpoints in the digital age

    Every clinical trial has an endpoint, a measure used to determine if the drug in question provides therapeutic benefit. ... There is no perfect overlap between clinical assessments used for guiding the treatment of a patient in a clinical care setting

  • The power of high-value, highly relevant content to support clinical decisions The power of high-value, highly relevant content to support clinical decisions

    by Sandrine Veillet. Physicians are lifelong learners – and that includes learning about clinical advancements that have the potential to change how they practice to provide the best possible care to their ... Offering HCPs a view into their

  • Real-world studies Real-world studies

    Insights gleaned from RWD captured during, or even as a by-product of clinical care can not only improve the efficiency of the drug development cycle, they can also streamline clinical ... With the right technology, infrastructure and support, RWD can be

  • The evolution of real-world studies The evolution of real-world studies

    The RWE-focused strategy enabled Pfizer to work round the rarity of male breast cancer and clinical trial enrolment challenges it creates. ... hard to enrol clinical trials and led to a growing role for real-world registries.

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    All this points to a revolution brought about by cell and gene therapy, not just in clinical care, but also in the pricing and reimbursement framework to support it. ... won’t need the high-cost allogeneic haematopoietic stem cell transplantation which

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... He brings more than 30 years of clinical and

  • Hamell Communications adds to team Hamell Communications adds to team

    She has worked in regulatory affairs, psychiatric care and early phase clinical trials.

  • David Haslam takes over as NICE chair David Haslam takes over as NICE chair

    responsibilities. As current national clinical adviser to the Care Quality Commission, Prof Haslam will be aware of the new challenges NICE faces in its revised role as the bulk of NHS ... ensure better outcomes for patients in a rapidly changing health

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics